What is Interpace Biosciences?
Interpace Biosciences is an emerging leader in personalized medicine, providing specialized services across the therapeutic value chain. The company's clinical services, operating under Interpace Diagnostics, offer clinically valuable molecular diagnostic tests, bioinformatics, and pathology services. These services are designed to evaluate cancer risk by utilizing advanced technology for improved patient diagnosis and management. Interpace has developed five commercialized molecular tests, including PancraGEN® for pancreatic cancer diagnosis and prognosis, PanDNA® for a focused analysis of key factors, ThyGeNEXT® for thyroid cancer diagnosis using next-generation sequencing, ThyraMIR®v2 for thyroid cancer diagnosis in conjunction with ThyGeNEXT®, and RespriDX® to differentiate primary lung cancer from metastatic origins. Additionally, BarreGEN®, a molecular assay for assessing the risk of Barrett's Esophagus progression to esophageal cancer, is currently in a clinical evaluation program (CEP) to gather physician usage data for safety, performance, and potential payer reimbursement.
How much funding has Interpace Biosciences raised?
Interpace Biosciences has raised a total of $3.6M across 1 funding round:
Stock Offering
$3.6M
Stock Issuance/Offering (2017): $3.6M, investors not publicly disclosed
What's next for Interpace Biosciences?
The recent major strategic investment signifies a pivotal moment for Interpace Biosciences, likely indicating a phase of accelerated scaling and market penetration. This capital infusion is expected to bolster the company's research and development efforts, expand its commercialization strategies for its suite of diagnostic tests, and potentially forge new strategic partnerships within the healthcare ecosystem. The company's focus on personalized medicine and advanced diagnostics aligns with the growing demand for targeted therapeutic applications, suggesting a trajectory towards becoming a key player in the precision oncology and diagnostics market.
See full Interpace Biosciences company page
